Kalampokis Evangelos, Nikou Theodora, Panteli Efthymia, Michailidis Dimitris, Trantas Emmanouil, Ververidis Filippos, Halabalaki Maria
Division of Pharmacognosy and Natural Products Chemistry, Department of Pharmacy, National and Kapodistrian University of Athens, Greece.
PharmaGnose S.A., 57th km Athens-Lamia National Road, Oinofyta, Greece.
J Chromatogr A. 2025 Aug 30;1757:466103. doi: 10.1016/j.chroma.2025.466103. Epub 2025 Jun 8.
Microbial production of bioactive molecules provides a promising alternative to traditional isolation or chemical synthesis approaches, enabling high-yield production of pure compounds without the need for heavy-metal catalysts, harsh conditions, or complex plant-based processes. Hydroxytyrosol (HT), a potent antioxidant with significant pharmacological properties, has attracted considerable interest due to its broad applications in pharmaceuticals, cosmetics, and food industries. While Escherichia coli systems have been effective for HT production, optimization of extraction yield and recovery process remain a challenge. Furthermore, isolation of HT and its metabolites continues to suffer from inefficiencies even when biosynthetic pathways are successful. Centrifugal techniques such as annular centrifugal extraction and partition chromatography methods e.g., Annular Centrifugal Extraction - ACE, Countercurrent chromatography - CCC, Centrifugal Partition Chromatography - CPC offer advantages over traditional methods, including the absence of solid stationary phases, reduced organic solvent use, speed, and scalability. However, these techniques have been underutilized in biotechnology workflows. Additionally, existing procedures often employ simplistic analytical methods, which lead to loss of valuable data for pathway monitoring, validation and metabolite discovery. This study presents a comprehensive workflow for the production, extraction, isolation, and identification of HT and derivatives from metabolically engineered E. coli biofactories. The workflow combines ACE for media extraction with CPC for high yield and purity HT isolation. It also emphasizes the analysis and structural elucidation of HT metabolites by means of HRMS/MS and 1 & 2D NMR, facilitating biosynthetic pathway monitoring and discovery of novel HT metabolites with potential enhanced biological activity. Using this approach, 23 compounds were isolated and identified contributing to the completion of the complex biosynthetic route of HT synthesis from l-tyrosine. This is first reported of direct isolation of pure HT metabolites from E. coli biofactories and to our knowledge the first application of liquid-liquid centrifugal techniques in the treatment of biotechnological materials.
生物活性分子的微生物生产为传统的分离或化学合成方法提供了一种有前景的替代方案,能够在无需重金属催化剂、苛刻条件或复杂的基于植物的工艺的情况下高产纯化合物。羟基酪醇(HT)是一种具有显著药理特性的强效抗氧化剂,因其在制药、化妆品和食品工业中的广泛应用而备受关注。虽然大肠杆菌系统已有效地用于HT生产,但提取产率和回收过程的优化仍然是一个挑战。此外,即使生物合成途径成功,HT及其代谢产物的分离仍然效率低下。诸如环形离心萃取和分配色谱法(例如环形离心萃取 - ACE、逆流色谱 - CCC、离心分配色谱 - CPC)等离心技术比传统方法具有优势,包括不存在固体固定相、减少有机溶剂使用、速度快和可扩展性。然而,这些技术在生物技术工作流程中未得到充分利用。此外,现有程序通常采用简单的分析方法,这导致在途径监测、验证和代谢产物发现方面丢失有价值的数据。本研究提出了一种从代谢工程改造的大肠杆菌生物工厂生产、提取、分离和鉴定HT及其衍生物的综合工作流程。该工作流程将用于培养基提取的ACE与用于高产率和高纯度HT分离的CPC相结合。它还强调通过高分辨率质谱/质谱(HRMS/MS)和一维及二维核磁共振(1 & 2D NMR)对HT代谢产物进行分析和结构解析,有助于生物合成途径监测和发现具有潜在增强生物活性的新型HT代谢产物。使用这种方法,分离并鉴定了23种化合物,有助于完成从L - 酪氨酸合成HT的复杂生物合成途径。这是首次报道从大肠杆菌生物工厂直接分离纯HT代谢产物,据我们所知,这也是液 - 液离心技术在生物技术材料处理中的首次应用。